NanoGroup SA
GGPW:NNG2.34
PLN
0.00
(0.00%)
NanoGroup SA
GPW:NNG
(Warsaw Stock Exchange)
Recent
price
2.34
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
PLN
•
in mil. unless spec.Working Capital
PLN
•
in mil. unless spec.Growth Rates
PLN
•
in mil. unless spec.Quarterly Revenue
PLN
•
in mil. unless spec.Quarterly Earnings Per Share
PLN
•
in mil. unless spec.Quarterly Dividends Per Share
PLN
•
in mil. unless spec.- Similar Companies
- Business
- NanoGroup S.A. (NNG.WA) operates as a biotechnology holding company focused on developing and commercializing nanotechnology-based medical solutions primarily in oncology and transplantology; it manages a portfolio of early-stage pre-clinical and IND projects through specialized subsidiaries including NanoVelos for polysaccharide nanoparticles in targeted drug therapies, nanoSanguis for respiratory gas transport systems such as blood substitutes, and DOTO Medical for aptamer platforms and medical devices. Core products and projects encompass the NanOX Recovery Box, a normothermic kidney perfusion device; NanOX 4 Kidney and NanOX 4 Liver, synthetic perfusion fluids for ex-vivo organ preservation that replicate blood's respiratory functions; PolEpi and other polysaccharide nanoparticle-based anticancer drug formulations; dextran nanoparticle conjugates; radiotherapeutics; human and veterinary blood substitutes; and AUX-001, an enhanced Nicorandil formulation for chronic angina targeting the U.S. market via FDA 505(b)(2) pathway. Founded in 2016 and headquartered at Rakowiecka 36 in Warsaw, Poland, the company lists on the Warsaw Stock Exchange since 2017 and conducts R&D in collaboration with institutes in the United States, China, and Italy while advancing projects toward GMP production and partnering windows in 2026-2027. Recent developments include a November 2025 investment of PLN 7.5 million (EUR 1.7 million) via ffVC fund subscription for acquiring preferred shares in Auxilius Pharma to accelerate AUX-001 Phase 1b trials and Phase 2 in 2026; a June 2025 acquisition of Pure Biologics' aptamer platform and DOTO Medical to expand into bioadsorbers and therapeutic applications; and ongoing preclinical advancements such as in-vitro dextran conjugate studies and non-GLP organ preservation trials planned for 2026. NanoGroup targets international biotech and pharma partners for licensing, operates from Poland with a focus on European and U.S. markets, and emphasizes diversified pipelines across pharmaceuticals, medical devices, and veterinary products to address unmet needs in transplantation and oncology.